NCT04323202View on ClinicalTrials.gov

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 4, 2020

Primary Completion Date

July 23, 2024

Study Completion Date

February 28, 2026

Conditions
Basal Cell Carcinoma of the Head and Neck
Interventions
DRUG

Pembrolizumab

Post Fine-cut CT: 4 doses of pembrolizumab (200mg) IV q 3 weeks. Post standard resection and reconstruction: 1 year of pembrolizumab (200mg) q 3 weeks (another 13 doses, thus 17 doses total)

OTHER

Tissue collection

Non-marginal tissue as well as pre-op biopsy tissue to be stored

Trial Locations (1)

44195

Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER